Available from:https:// www.fda.gov/downloads/drugs/guidances/ucm292362.pdf. 14. European Medicines Agency. Guideline on the investigation of drug interactions. 2012 June 21 [cited 2017 Oct 20]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/ Scientific_guideline/2012/07/WC500129606.pdf. 15. Bækdal TA, Blicher TM, Donsmark M, et al. Safety, tolerability, and pharmacokinetics of single escalating doses of oral semaglutide in healthy male subjects. Diabetes.2017;66(Suppl.1):1191– P. 16. Shirasaka Y, Sager JE, Lutz JD, et al. Inhibition of CYP2C19 and CYP3A4 by omeprazole metabolites and their contribution to drug-drug interactions. Drug Metab Dispos. 2013;41:1414 – 1424. 17. Viani F, Verdú EF, Idström JP, et al. Effect of omeprazole on regional and temporal variations in intragastric acidity. Digestion. 2002;65(1):2– 10. 18. Prichard PJ, Yeomans ND, Mihaly GW, et al. Omeprazole: a study of its inhibition of gastric pH and oral pharmacokinetics after morning or evening dosage. 